Over expression of GroESL in Cupriavidus necator for heterotrophic and autotrophic isopropanol production.

TitleOver expression of GroESL in Cupriavidus necator for heterotrophic and autotrophic isopropanol production.
Publication TypeJournal Article
Year of Publication2017
AuthorsMarc, J, Grousseau, E, Lombard, E, Sinskey, AJ, Gorret, N, Guillouet, SE
JournalMetab Eng
Date Published2017 Jul
Keywords2-Propanol, Bacterial Proteins, Chaperonins, Cupriavidus necator, Gene Expression

We previously reported a metabolic engineering strategy to develop an isopropanol producing strain of Cupriavidus necator leading to production of 3.4gL isopropanol. In order to reach higher titers, isopropanol toxicity to the cells has to be considered. A toxic effect of isopropanol on the growth of C. necator has been indeed observed above a critical value of 15gL. GroESL chaperones were first searched and identified in the genome of C. necator. Native groEL and groES genes from C. necator were over-expressed in a strain deleted for PHA synthesis. We demonstrated that over-expressing groESL genes led to a better tolerance of the strain towards exogenous isopropanol. GroESL genes were then over-expressed within the best engineered isopropanol producing strain. A final isopropanol concentration of 9.8gL was achieved in fed-batch culture on fructose as the sole carbon source (equivalent to 16gL after taking into account evaporation). Cell viability was slightly improved by the chaperone over-expression, particularly at the end of the fermentation when the isopropanol concentration was the highest. Moreover, the strain over-expressing the chaperones showed higher enzyme activity levels of the 2 heterologous enzymes (acetoacetate carboxylase and alcohol dehydrogenase) of the isopropanol synthetic operon, translating to a higher specific production rate of isopropanol at the expense of the specific production rate of acetone. Over-expressing the native chaperones led to a 9-18% increase in the isopropanol yield on fructose.

Alternate JournalMetab Eng
Citation Key61
PubMed ID28591561